Pinocytosis as the Biological Mechanism That Protects Pgp Function in Multidrug Resistant Cancer Cells and in Blood-Brain Barrier Endothelial Cells
暂无分享,去创建一个
Cyril Rauch | Ziad Omran | Chloe Whitehouse | Majed Halwani | Mazin A. Zamzami | Othman A. Baothman | O. Baothman | M. Zamzami | C. Rauch | Z. Omran | M. Halwani | Chloe Whitehouse
[1] Huirong Shi,et al. Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. , 2017, Oncotarget.
[2] C. Rauch. The “Multi” of Drug Resistance Explained by Oscillating Drug Transporters, Drug–Membrane Physical Interactions and Spatial Dimensionality , 2011, Cell Biochemistry and Biophysics.
[3] F. Shephard,et al. Importance of the Difference in Surface Pressures of the Cell Membrane in Doxorubicin Resistant Cells That do not Express Pgp and ABCG2 , 2013, Cell Biochemistry and Biophysics.
[4] H. Saragovi,et al. Novel approaches for targeted cancer therapy. , 2004, Current cancer drug targets.
[5] R. Assoian,et al. ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition. , 2008, Cancer research.
[6] O. Jensen,et al. On a biophysical and mathematical model of Pgp-mediated multidrug resistance: understanding the “space–time” dimension of MDR , 2009, European Biophysics Journal.
[7] A. Pluen,et al. Multi drug resistance-dependent “vacuum cleaner” functionality potentially driven by the interactions between endocytosis, drug size and Pgp-like transporters surface density , 2007, European Biophysics Journal.
[8] C. Rauch,et al. Acid-mediated Lipinski’s second rule: application to drug design and targeting in cancer , 2014, European Biophysics Journal.
[9] Ashraf N. Abdalla,et al. Design, synthesis, and in vitro biological evaluation of 14-hydroxytylophorine-dichloroacetate co-drugs as antiproliferative agents. , 2019, Chemical & pharmaceutical bulletin.
[10] N. Johnson,et al. Systemic cancer therapy: achievements and challenges that lie ahead , 2013, Front. Pharmacol..
[11] J. González-Ros,et al. Ultrastructural alterations in plasma membranes from drug-resistant P388 murine leukemia cells. , 1990, Biochimica et biophysica acta.
[12] S. Paine,et al. Can long range mechanical interaction between drugs and membrane proteins define the notion of molecular promiscuity? Application to P-glycoprotein-mediated multidrug resistance (MDR). , 2013, Biochimica et biophysica acta.
[13] David J. Begley,et al. Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.
[14] C. Rauch. On the relationship between drug’s size, cell membrane mechanical properties and high levels of multi drug resistance: a comparison to published data , 2009, European Biophysics Journal.
[15] M. Melamed,et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[16] C. Rauch,et al. Physical and biological characteristics of multi drug resistance (MDR): An integral approach considering pH and drug resistance in cancer. , 2017, Seminars in cancer biology.
[17] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[18] W. Pardridge. The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.
[19] Jean-Pierre Gillet,et al. Mechanisms of multidrug resistance in cancer. , 2010, Methods in molecular biology.
[20] E. Farge,et al. Endocytosis switch controlled by transmembrane osmotic pressure and phospholipid number asymmetry. , 2000, Biophysical journal.
[21] A. Mobasheri,et al. On Some Aspects of the Thermodynamic of Membrane Recycling Mediated by Fluid Phase Endocytosis: Evaluation of Published Data and Perspectives , 2010, Cell Biochemistry and Biophysics.